Technologies
PDF


WARF: P110006US01

  • Assigned to WARF as biological material.

Compounds to Treat Hyperlipidemia and Fatty Liver Disease


INVENTORS -

Mark Keller, Alan Attie, Sheldon Engelhorn, Nikolai Sepetov, Sergei Romanov, David Bernlohr

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a novel set of drug-like compounds shown to be potent and selective inhibitors of the protein L-FABP.
OVERVIEWHyperlipidemia is a condition strongly associated with obesity and is an independent risk factor for the development of coronary heart disease. To help combat hyperlipidemia, the pharmaceutical industry has focused on a protein, MTP, known to play a role in cardiovascular disease. Certain MTP inhibitors have been developed to lower levels of ‘bad’ cholesterol and triglycerides, and decrease heart disease.

Unfortunately, while MTP inhibitors have been shown to be effective, their use can lead to the development of fatty liver disease, or hepatosteatosis. Highly desirable would be a new drug that could prevent this serious side effect.
THE INVENTIONUW–Madison researchers and collaborators have developed compounds that can be used to prevent fatty liver disease resulting from MTP inhibitors. The compounds selectively inhibit the liver-specific isoform of fatty acid binding protein (L-FABP). Suppression of L-FABP activity has been shown to block the fatty liver side effect caused by MTP inhibitors without diminishing the latter’s lipid-lowering benefits.
BUSINESS OPPORTUNITY
  • The U.S. obesity drug market has been valued at more than $130 million.
  • Currently there are no drugs that specifically target L-FABP as a method to ameliorate fatty liver disease.
APPLICATIONS
  • Small molecule L-FABP inhibitors can be used in conjunction with MTP inhibitors to treat hyperlipidemia and fatty liver disease
  • Potential new weapon against obesity and possibly heart disease
KEY BENEFITS
  • New compounds are potent and selective.
  • No comparable drugs currently on the market
STAGE OF DEVELOPMENTThe researchers have demonstrated that dual inhibition of L-FABP and MTP with small molecules is a viable treatment strategy for ameliorating hyperlipidemia without causing fatty liver disease.

The development of this technology was supported by the WARF Accelerator Program. The Accelerator Program selects WARF’s most commercially promising technologies and provides expert assistance and funding to enable achievement of commercially significant milestones. WARF believes that these technologies are especially attractive opportunities for licensing.
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact John Nagel at jnagel@warf.org or 608-960-9848.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.